essence trial semaglutide Improves Histology in MASH: Phase 3 Metabolic dysfunction-associated steatotic liver disease

doi:10.1074/jbc.274.13.8570

A research review of 28 trials and 23,000 patients showed that tirzepatide produces slightly more weight loss than semaglutide compared to a placebo

These findings from diverse PRS studies illustrate both the potential and the inherent challenges in using genetic scores to elucidate the link between MDD and T2DM

& Bartizal, K

Linagliptin (10 mg/kg) lowered peak glucose concentration, which occurred at 15 min in all mice, while Ex9 impaired basal glucose and tolerance to an oral glucose load in VilCre control mice but had no effect in Gcg RA VilCre or Gcg RA Null mice (Fig

doi: 10.1152/ajpgi.00156.2010 244